Baidu
map

Hypertension:门诊治疗高血压患者左室肥厚风险知多少?

2016-12-03 xing.T MedSci原创

尽管更积极的降压治疗,21%的高血压患者出现明确的左心室肥厚。调整混杂因素后,发生左心室肥厚的风险与女性尤为相关,当存在肥胖的情况时其风险将进一步增加。

在接受降压治疗的高血压患者中报道左心室肥厚发生发展的研究较少,近日,心血管权威杂志Hypertension上发表一篇来自意大利费德里克二世大学高血压病研究中心的Raffaele Izzo医生及其团队的研究文章,研究人员评估了在接受降压治疗的高血压患者中左心室肥厚发生率,这些研究对象来自坎帕尼亚致敬网络登记处。 

研究人员前瞻性地分析了4290例至少随访一年的高血压患者(50.3±11.1岁,40%为女性),在研究之初无左心室肥厚。左心室肥厚发生是指通过超声心动图第一次检测到左室质量指数47g/m2.7(女性)或50g/m2.7(男性)。中位随访时间为48个月,研究人员发现其中915例患者(21.3%)发生左心室肥厚。这群患者的主要特征为:年龄较大,更多的为女性,肥胖(P0.0001),较高的基础空腹血糖、舒张压、收缩压、左心室重量指数,降低的心率和肾小球滤过率,较长的高血压病史和随访时间和随访期间更高的平均收缩压(所有P均<0.05),而且采用钙通道阻滞剂和利尿剂治疗很常见(P均<0.02)。 

在多变量Cox回归分析中,研究人员发现左心室肥厚的发生与更大年龄、女性、肥胖、在随访过程中更高的平均收缩压和较大的左室基础质量指数存在独立相关性(P均<0.02)。根据肥胖和性别将患者进行分类,在男性和女性中,肥胖与左心室肥厚发生风险增加独立相关(男性中肥胖者比上非肥胖者风险比为1.34;可信区间为1.05-1.72P=0.019;女性在肥胖者比上非肥胖者的风险比为1.34;可信区间为1.08-1.66P=0.007)。 

尽管更积极的降压治疗,21%的高血压患者出现明确的左心室肥厚。调整混杂因素后,发生左心室肥厚的风险与女性尤为相关,当存在肥胖的情况时其风险将进一步增加。 

原始出处: 

Raffaele Izzo, et al. Development of Left Ventricular Hypertrophy in Treated Hypertensive Outpatients The Campania Salute Network. Hypertension. November 28, 2016. 

本文系梅斯医学MedSci原创编译整理转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2038563, encodeId=e07320385637b, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Mar 21 11:52:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726242, encodeId=fd441e262423d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Oct 03 23:52:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160366, encodeId=3c7f160366b8, content=除血压外,其他SCVD的危险因素也应控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161224/IMG585DA5E26B9F44696.jpg, createdBy=565a98798, createdName=susice, createdTime=Mon Dec 05 08:24:01 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448170, encodeId=19cf14481e0d3, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Mon Dec 05 05:52:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501097, encodeId=9d35150109e9d, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon Dec 05 05:52:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160007, encodeId=e71016000e2b, content=期待答案!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sat Dec 03 22:37:05 CST 2016, time=2016-12-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2038563, encodeId=e07320385637b, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Mar 21 11:52:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726242, encodeId=fd441e262423d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Oct 03 23:52:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160366, encodeId=3c7f160366b8, content=除血压外,其他SCVD的危险因素也应控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161224/IMG585DA5E26B9F44696.jpg, createdBy=565a98798, createdName=susice, createdTime=Mon Dec 05 08:24:01 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448170, encodeId=19cf14481e0d3, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Mon Dec 05 05:52:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501097, encodeId=9d35150109e9d, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon Dec 05 05:52:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160007, encodeId=e71016000e2b, content=期待答案!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sat Dec 03 22:37:05 CST 2016, time=2016-12-03, status=1, ipAttribution=)]
    2017-10-03 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=2038563, encodeId=e07320385637b, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Mar 21 11:52:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726242, encodeId=fd441e262423d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Oct 03 23:52:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160366, encodeId=3c7f160366b8, content=除血压外,其他SCVD的危险因素也应控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161224/IMG585DA5E26B9F44696.jpg, createdBy=565a98798, createdName=susice, createdTime=Mon Dec 05 08:24:01 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448170, encodeId=19cf14481e0d3, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Mon Dec 05 05:52:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501097, encodeId=9d35150109e9d, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon Dec 05 05:52:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160007, encodeId=e71016000e2b, content=期待答案!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sat Dec 03 22:37:05 CST 2016, time=2016-12-03, status=1, ipAttribution=)]
    2016-12-05 susice

    除血压外,其他SCVD的危险因素也应控制

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2038563, encodeId=e07320385637b, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Mar 21 11:52:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726242, encodeId=fd441e262423d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Oct 03 23:52:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160366, encodeId=3c7f160366b8, content=除血压外,其他SCVD的危险因素也应控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161224/IMG585DA5E26B9F44696.jpg, createdBy=565a98798, createdName=susice, createdTime=Mon Dec 05 08:24:01 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448170, encodeId=19cf14481e0d3, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Mon Dec 05 05:52:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501097, encodeId=9d35150109e9d, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon Dec 05 05:52:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160007, encodeId=e71016000e2b, content=期待答案!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sat Dec 03 22:37:05 CST 2016, time=2016-12-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2038563, encodeId=e07320385637b, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Mar 21 11:52:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726242, encodeId=fd441e262423d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Oct 03 23:52:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160366, encodeId=3c7f160366b8, content=除血压外,其他SCVD的危险因素也应控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161224/IMG585DA5E26B9F44696.jpg, createdBy=565a98798, createdName=susice, createdTime=Mon Dec 05 08:24:01 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448170, encodeId=19cf14481e0d3, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Mon Dec 05 05:52:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501097, encodeId=9d35150109e9d, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon Dec 05 05:52:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160007, encodeId=e71016000e2b, content=期待答案!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sat Dec 03 22:37:05 CST 2016, time=2016-12-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2038563, encodeId=e07320385637b, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Mar 21 11:52:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726242, encodeId=fd441e262423d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Oct 03 23:52:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160366, encodeId=3c7f160366b8, content=除血压外,其他SCVD的危险因素也应控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161224/IMG585DA5E26B9F44696.jpg, createdBy=565a98798, createdName=susice, createdTime=Mon Dec 05 08:24:01 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448170, encodeId=19cf14481e0d3, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Mon Dec 05 05:52:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501097, encodeId=9d35150109e9d, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon Dec 05 05:52:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160007, encodeId=e71016000e2b, content=期待答案!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sat Dec 03 22:37:05 CST 2016, time=2016-12-03, status=1, ipAttribution=)]
    2016-12-03 知难而进

    期待答案!

    0

相关资讯

JACC心衰子刊:人到中年做好这三件事,可降低86%心衰风险

治疗心衰最好的药物就是预防,而近期JACC心衰子刊上发表的一项研究表明,人到中年,如果能管理好自己的健康,远离高血压、肥胖和糖尿病,就能在余生降低86%的心衰风险。 这项研究中,研究者共对两组人群的相关数据进行了分析,其中一组共纳入19,000位受试者,平均年龄在45岁;另一组共纳入24,000位受试者,平均年龄在55岁。前者在随访516,537人年期间共有1700人发生心衰,后者在随访

盘点:近期高血压亮点研究一览

2016年发布了众多有关高血压相关重要研究,梅斯小编就近期高血压领域重要的研究进行回顾与整理,与大家分享。【1】JACC:白大衣高血压与心血管风险之间究竟有着怎样的关联?来自美国的研究人员使用了来自基于群体的11项队列IDACO(关于心血管结果的动态血压监测的国际数据库)研究的数据,该研究比较了653例WCH患者和653名健康对照者常规血压测量的日间动态血压监测数据。欧洲高血压指南被用于评估5

2016AHA科学声明:慢性心衰合并高血压,肥胖,糖尿病,高脂血症和代谢综合征的管理以及分摊风险发布

2016年10月,美国心脏协会(AHA)发布了关于慢性心衰合并高血压,肥胖,糖尿病,高脂血症和代谢综合征的管理以及分摊风险的科学声明。高血压,糖尿病,肥胖,高脂血症和代谢综合征是心衰患者常见的合并症并且影响临床结局。本文的主要目的是总结了分摊风险的相关数据并对心衰患者合并高血压,肥胖,糖尿病,高脂血症和代谢综合征的管理提供指导。全文获取:下载地址:指南下载 (需要扣积分2分, 

中国山东限盐项目:胖人更应限盐,也应重视补充饮食钾

清华大学北京清华长庚医院张啸飞和中国疾控中心慢病中心马吉祥等对山东省-原卫生部联合减盐防控高血压项目(SMASH)人群进行的研究提示,对于超重和肥胖者,高钠低钾饮食对血压的影响更大。 张啸飞表示,钠钾比例无论在超重人群还是全部人群,与 血压都呈正相关关系,与钾呈负相关关系。要关注膳食摄入盐水平,即摄入钠水平,更需要关心钾水平、钠钾比例水平,尤其是肥胖人群。研究在一个来自山东的人群中开展,

PLOS ONE:摄入较多的茶多酚或可降低高血压的发生风险

高血压是心血管疾病的一个重要危险因素,目前已证实饮食是预防和控制高血压的因素。此外,流行病学研究表明多酚摄入量和心血管疾病之间呈反比关系。本研究旨在探究多酚的摄入和高血压之间的关联。研究共纳入了来自圣保罗健康调查的550名成人。通过两个24小时膳食回顾来评估其饮食。使用多源方法来计算参与者多酚的常规摄入量。使用多元Logistic回归分析对探究茶多酚摄入总量与高血压之间的关联。校正潜在的混杂因素后

Circ Res:连接疟疾和高血压的桥梁—升高的血管紧张素II

高水平的血管紧张素Ⅱ和免受疟疾肆虐的保护作用之间存在的因果关系,可以为在非洲和南亚裔的人群中观察到的高血压患病率增加的现象提供了一个可能的解释。此外,这种潜在的因果关系也可能是一种有效地治疗脑型疟疾的独特的方法。

Baidu
map
Baidu
map
Baidu
map